Green P M, Bentley D R, Mibashan R S, Nilsson I M, Giannelli F
Division of Medical and Molecular Genetics, UMDS, London, UK.
EMBO J. 1989 Apr;8(4):1067-72. doi: 10.1002/j.1460-2075.1989.tb03474.x.
Direct sequencing of amplified genomic DNA has been used to investigate the molecular basis of haemophilia B and thus identify specific amino acids that are essential for maintenance of structure or function of factor IX. Substitution of Cys 336, Asn 120 results in loss of circulating factor IX antigen and deletion of Arg 37 in gross reduction of circulating protein and loss of activity, while substitution of Arg -4, Arg 333, Asp 64 and Pro 55 cause loss of function without marked reduction in protein serum levels. Frameshift or point mutations resulting in marked loss of coding information are found in patients who develop antibodies to administered factor IX. An enhanced rate of mutation is evident at two CpG dinucleotides in the factor IX gene, which accounts for approximately 25% of all point mutations causing haemophilia B known to date. Direct sequencing of mutations also permits, for the first time, rapid and unequivocal prenatal and carrier diagnoses, in all cases, by eliminating the need for informative segregation of markers.
对扩增的基因组DNA进行直接测序已被用于研究B型血友病的分子基础,从而确定对于维持凝血因子IX结构或功能至关重要的特定氨基酸。半胱氨酸336、天冬酰胺120的替换导致循环凝血因子IX抗原丧失,精氨酸37的缺失导致循环蛋白大幅减少并丧失活性,而精氨酸-4、精氨酸333、天冬氨酸64和脯氨酸55的替换则导致功能丧失,但蛋白血清水平无明显降低。在对所给予的凝血因子IX产生抗体的患者中发现了导致编码信息显著丧失的移码或点突变。在凝血因子IX基因的两个CpG二核苷酸处,突变率明显增加,这约占迄今为止已知的导致B型血友病的所有点突变的25%。对突变进行直接测序还首次使得在所有情况下都能通过无需标记物的信息性分离来快速明确地进行产前和携带者诊断。